Leerink Partners analyst Marc Goodman maintained a Buy rating on AC Immune SA (ACIU – Research Report) on March 14 and set a price target of $9.00.
Marc Goodman has given his Buy rating due to a combination of factors, including AC Immune’s promising pipeline and financial stability. The company is set to release several key data points in 2025, such as interim results from their Phase 2 trials for Parkinson’s and Alzheimer’s diseases, which could significantly impact their market position.
Additionally, AC Immune’s robust cash reserves of CHF 166 million provide a financial runway into 2027, ensuring stability and continued investment in their diverse projects. The company’s strategic partnerships and innovative platform technologies further bolster confidence in its long-term growth prospects, making it an attractive investment opportunity.
Goodman covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Evolus, and Biohaven Ltd.. According to TipRanks, Goodman has an average return of 4.4% and a 44.81% success rate on recommended stocks.